Opportunities for PET to deliver clinical benefit in cancer

breast cancer as a paradigm

Ian N Fleming, Fiona J Gilbert, Ken A Miles, David Cameron

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.
Original languageEnglish
Pages (from-to)144-152
Number of pages9
JournalCancer Imaging
Volume10
Issue number1
Publication statusPublished - 6 Jul 2010

Fingerprint

Positron-Emission Tomography
Breast Neoplasms
Neoplasms
Residual Neoplasm
Cell Biology
Phosphorylation
Apoptosis
Technology
Glucose
Hypoxia

Keywords

  • assessing therapy response
  • breast cancer
  • diagnosis
  • identification of recurrence
  • pharmacological biomarker
  • positron emission tomography
  • predictive biomarker
  • staging
  • surrogate response biomarker
  • tumour subtyping

Cite this

Opportunities for PET to deliver clinical benefit in cancer : breast cancer as a paradigm. / Fleming, Ian N; Gilbert, Fiona J; Miles, Ken A; Cameron, David.

In: Cancer Imaging, Vol. 10, No. 1, 06.07.2010, p. 144-152.

Research output: Contribution to journalArticle

Fleming, IN, Gilbert, FJ, Miles, KA & Cameron, D 2010, 'Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm', Cancer Imaging, vol. 10, no. 1, pp. 144-152.
Fleming, Ian N ; Gilbert, Fiona J ; Miles, Ken A ; Cameron, David. / Opportunities for PET to deliver clinical benefit in cancer : breast cancer as a paradigm. In: Cancer Imaging. 2010 ; Vol. 10, No. 1. pp. 144-152.
@article{bb39e19261a14166942908ab844e0ece,
title = "Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm",
abstract = "The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90{\%} of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.",
keywords = "assessing therapy response, breast cancer, diagnosis, identification of recurrence, pharmacological biomarker, positron emission tomography, predictive biomarker, staging , surrogate response biomarker, tumour subtyping",
author = "Fleming, {Ian N} and Gilbert, {Fiona J} and Miles, {Ken A} and David Cameron",
year = "2010",
month = "7",
day = "6",
language = "English",
volume = "10",
pages = "144--152",
journal = "Cancer Imaging",
issn = "1470-7330",
publisher = "e-med",
number = "1",

}

TY - JOUR

T1 - Opportunities for PET to deliver clinical benefit in cancer

T2 - breast cancer as a paradigm

AU - Fleming, Ian N

AU - Gilbert, Fiona J

AU - Miles, Ken A

AU - Cameron, David

PY - 2010/7/6

Y1 - 2010/7/6

N2 - The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.

AB - The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.

KW - assessing therapy response

KW - breast cancer

KW - diagnosis

KW - identification of recurrence

KW - pharmacological biomarker

KW - positron emission tomography

KW - predictive biomarker

KW - staging

KW - surrogate response biomarker

KW - tumour subtyping

M3 - Article

VL - 10

SP - 144

EP - 152

JO - Cancer Imaging

JF - Cancer Imaging

SN - 1470-7330

IS - 1

ER -